PMDA Perspective on Regulatory Commitments

Yoshihiro Matsuda, Ph.D.

Office of Standards and Guidelines Development
Pharmaceuticals and Medical Devices Agency (PMDA)
Introduction of PMDA

• Name: Pharmaceuticals and Medical Devices Agency
• Date of Establishment: In April 2004
• Established as an Incorporated Administrative Agency

PMDA Organization

Office of International Programs
Office of Regulatory Science
Office of Standards and Guidelines Development
Office of Cellular and Tissue-based Products
Office of Conformity Audit
Office of New Drug
Office of Relief Funds
Office of Vaccines and Blood Products
Office of Medical Devices
Office of Safety
Office of GMP/QMS Inspection
Office of OTC/Generic Drugs
PMDA’s Safety Triangle

Unique Three-pillar System
Securing Nation’s Safety

Review
Reduction in Risk

Safety
Continuous risk mitigation efforts

Japanese Citizens

Relief
Relief measures for health damage caused by risk factors

2014 AAPS Annual Meeting and Exposition
Flowchart of Reviewing Process

1. Submission
2. Review Report
3. Approval

Applicant

MHLW
Ministry of Health, Labour and Welfare

The Pharmaceutical Affairs and Food Sanitation Council

PMDA

2014 AAPS Annual Meeting and Exposition
GMP Inspection System

MHLW

Control over inspectorates
Ultimate responsibility

PMDA
Inspectorate

Prefectures
47 Inspectorates

PMDA is partially vested with authority of MHLW

Prefectures are vested with part of MHLW’s authority to exercise local autonomy.
## GMP Inspections by PMDA and Prefectural Governments (47)

<table>
<thead>
<tr>
<th></th>
<th>Domestic Site</th>
<th>Foreign Site</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New Drugs, Biological Products, Radio Pharmaceuticals</strong></td>
<td>PMDA</td>
<td>PMDA</td>
</tr>
<tr>
<td><strong>Other Drugs</strong></td>
<td>Pref. Gov.</td>
<td>PMDA</td>
</tr>
</tbody>
</table>
Relationship between Application Form and CTD Documents in Japan

Application Form (included in Module 1)

Module 2 (QOS)

CTD Module 3

Raw data

2014 AAPS Annual Meeting and Exposition
What is the Application Form?

- Contents provided in the Application Form by applicants are dealt with as “matters subject to approval.”
- Contents described in Approval letter are “legally binding” approval matters.
Approval Matters
(Contents of Application Form)

- Japanese accepted name (non-proprietary name)
- Brand name
- Composition
- Manufacturing process, including control of materials
- Specifications and analytical procedures
- Dosage and administration
- Indications
- Storage condition and shelf-life
- Manufacturing sites information
Matters to be described in manufacturing field of Application Form

- All processes from raw material(s) to packaging process
  - A flow diagram of manufacturing process including:
    - Raw materials
    - Charge-in amount
    - Yield
    - Solvent
    - Intermediate materials
    - Process parameter (e.g. Target Value/Set Value)
  - A narrative description of manufacturing process
    - Acceptance criteria of starting material(s) and intermediate materials
    - In process control, Design Space and RTRT etc.
### Post-authorization Procedure

<table>
<thead>
<tr>
<th>Risk of Changes</th>
<th>Japan</th>
<th>US</th>
<th>EU</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td><strong>Partial change</strong> (Application for approval of variation)</td>
<td><strong>Major change</strong> (Prior approval supplement)</td>
<td><strong>Type II variation</strong> (Application for approval of variation)</td>
</tr>
<tr>
<td>Moderate</td>
<td><strong>Minor change</strong> (Notification within 30 days after implementation or shipping)</td>
<td><strong>Moderate change</strong> 1) Supplement-changes being effected (CBE) in 30 days 2) Supplement-changes being effected (CBE)</td>
<td><strong>Type IB variation</strong> (Notification before implementation and MAHs must wait a period of 30 days)</td>
</tr>
<tr>
<td>Low</td>
<td><strong>Minor change</strong> (Annual report)</td>
<td><strong>Type IA \textsubscript{IN} variation</strong> (Immediate notification)</td>
<td><strong>Type IA variation</strong> (Notification within 12 months after implementation)</td>
</tr>
</tbody>
</table>
Examples of Matter Subject to a Partial Change Application

- Change in
  - principle of unit operation of critical process
  - materials of primary packaging component
  - matters for aseptic manufacturing
  - specification of intermediate product in case that the test is performed instead of release test of final drug product...etc.

But we can judge that on a case-by-case basis.

Flexibility
Flexible Assessment

- Only contents of Application Form will be legally binding matters as the approval letter.
- CTD Module 2 and 3 are just review documents.
- Assessors can set the post approval change classification for each procedure and process parameter on Application Form(Approval Letter).
How to describe partial change matters and minor change matters

- Enter target/set values of process parameters and standard charge-in amounts in:
  - 《 》: partial change matter
  - 『 』: minor change matter

- Enter items other than target/set values in:
  - “ ”: minor change matter
  - No parentheses: partial change matter
Example of manufacturing description on Application Form

Step 1 (Critical Step)

CP-6【(230kg)】，tetrahydrofuran【(1300L)】，sodium carbonate【(42.4kg)】 are combined. Ethyl chloroformate “158 ~ 592kg” is added and the mixture is heated at temperature up to reflux. ・・・・

Water (”25 to 35%” *weight per weight of ethanol) is added and the mixture is stirred at 『20℃』.

* Water quantity is relative to the ethanol quantity, ethanol volume and crystallization temperature are parameters establishing Design Space which controls the quantity of total impurities.

Acknowledgement: Sakuramil (Sakuramil S2 mock)
Benefits of Regulatory system in Japan

☐ Transparency
- We can clearly share the regulatory commitments between the applicant and regulators.
- Module 2 can be a good communication document because Module 2 is just a review document and applicants can write their narrative on Quality Overall Summary freely.

☐ Efficiency
- Quality Overall Summary can facilitate our assessment because of the primary review document in Japan.
- Members of a MHLW’s council and external specialists can understand the contents of the application smoothly by the Quality Overall Summary.
Challenges

- It seems to be difficult to summarize the QbD approaches in Module 2 in brief.
- How to encourage continual improvement much more?
ICH Informal Quality Discussion Group (IQDG) in Minneapolis, 2014

- IQDG Quality Workshop
  - 2003 Quality Vision expectation achieved

However, more efforts needed to fully address challenges and strengthen product lifecycle management

ICH Q12 : Lifecycle Management
Lifecycle Management

- Problem statement
  - Implementation of ICH Q8/Q11, Q9 and Q10 provides opportunities for a more science and risk based approach to assessing changes across the lifecycle
  - Main emphasis is during the Development stage
  - Opportunities and benefits have not been fully realized (or enabled), and the envisioned operational flexibility has not been achieved
  - We now need to focus on the Commercial Manufacturing phase of the lifecycle
ICH Q12 Concept Paper

- Key words for Issues to be resolved
  - Regulatory commitments
  - Post approval change management system
  - Criteria for a harmonized risk-based change management system
  - Knowledge management system
  - Post-Approval Change Management Plans and Protocols
Regulatory Commitments

- The regions differ in their interpretation of “regulatory commitments” (e.g., manufacturing process and controls).

- In Japan, regulatory commitments are the contents of Application Form.
  - Regulatory commitments are clearly separated by Application Form because CTD M2 and M3 are references for a review.
Post approval change management system

- Enhance use of regulatory tools for prospective change management

- In Japan the application form can define a classification of post-authorization procedure during a review period.

- However we have no post-approval change management protocol or plan as in US/Europe.
### ICH Future Quality Topics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>June</td>
<td>Nov</td>
<td>June</td>
<td>Nov</td>
<td>June</td>
<td>Nov</td>
<td>June</td>
</tr>
<tr>
<td>ICH Q12 Lifecycle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management EWG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>API-SM IWG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QOS EWG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analytical procedures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EWG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous Manufacturing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EWG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2014 AAPS Annual Meeting and Exposition
Thank you for your attention